AM 164 is a phase II inpatient, placebo-controlled monotherapy trial of the experimental anticonvulsant remacemide in adults with refractory partial epilepsy whose regular anticonvulsants have been discontinued during a routine hospital admission on 8 Long immediately preceding this study for EEG/video telemetry to determine their suitability for surgical treatment of seizures. The study will also evaluate the safety, tolerability, and efficacy of remacemide.
Showing the most recent 10 out of 634 publications